KRAS and neoplasm: Furthermore, they also showed that suppression of KRAS G12V by retroviral siRNA caused loss of tumorigenicity of pancreatic cancer cells harboring KRAS G12V in a subcutaneous xenograft, proving that siRNA has power as a tumor-specific gene therapy tool (35).